Literature DB >> 20401724

Pulmonary non-Hodgkin's lymphoma developed during long-term methotrexate therapy for rheumatoid arthritis.

Huiying Wang1, Dandan Wu, Hua Xiang, Aifeng Chen, Jin Liu.   

Abstract

Methotrexate is effective in treating rheumatoid arthritis (RA). Some reports have discussed the possible association between methotrexate and lymphoma. Here, we report a case of pulmonary non-Hodgkin's lymphoma (NHL) developed after 11 years' methotrexate therapy for RA. Biopsy of the pulmonary mass demonstrated a diffuse large B-cell lymphoma. After withdrawal of methotrexate without any other intervention for 4 weeks, a significant reduction in the size of the lymphoma was observed. The causative relationship between methotrexate and pulmonary lymphoma is suggested by the persistent remission after stopping methotrexate therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20401724     DOI: 10.1007/s00296-010-1496-0

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  9 in total

Review 1.  Rheumatoid arthritis, methotrexate, and lymphoma: risk substitution, or cat and mouse with Epstein-Barr virus?

Authors:  G Starkebaum
Journal:  J Rheumatol       Date:  2001-12       Impact factor: 4.666

Review 2.  Spontaneous remission of marginal zone B cell lymphoma in a patient with seropositive rheumatoid arthritis after discontinuation of infliximab-methotrexate treatment.

Authors:  R Thonhofer; M Gaugg; M Kriessmayr; H J Neumann; L Erlacher
Journal:  Ann Rheum Dis       Date:  2005-07       Impact factor: 19.103

3.  Methotrexate-induced pulmonary non-Hodgkin lymphoma.

Authors:  Gavin C Mackie; Judith M Pohlen
Journal:  Clin Nucl Med       Date:  2006-05       Impact factor: 7.794

4.  Remission of a primary thyroid lymphoma after methotrexate withdrawal.

Authors:  Quirijn de Mast; Joost Haverman; Paetrick M Netten; Harm A M Sinnige
Journal:  Clin Endocrinol (Oxf)       Date:  2006-06       Impact factor: 3.478

Review 5.  Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases.

Authors:  E Salloum; D L Cooper; G Howe; J Lacy; G Tallini; J Crouch; M Schultz; J Murren
Journal:  J Clin Oncol       Date:  1996-06       Impact factor: 44.544

6.  Epstein-Barr virus infection associated hepatic lymphoma in a patient treated with methotrexate for rheumatoid arthritis.

Authors:  Martin Soubrier; Stéphanie Arrestier; Sarah Bouloudian; Jean-Jacques Dubost; Jean-Michel Ristori
Journal:  Joint Bone Spine       Date:  2006-01-30       Impact factor: 4.929

7.  Remission of lymphoma after withdrawal of methotrexate in rheumatoid arthritis: relationship with type of latent Epstein-Barr virus infection.

Authors:  Takuya Miyazaki; Katsumichi Fujimaki; Yukari Shirasugi; Fumiaki Yoshiba; Manabu Ohsaka; Koji Miyazaki; Etsuko Yamazaki; Rika Sakai; Jun-Ichi Tamaru; Kenji Kishi; Heiwa Kanamori; Masaaki Higashihara; Tomomitsu Hotta; Yoshiaki Ishigatsubo
Journal:  Am J Hematol       Date:  2007-12       Impact factor: 10.047

8.  Methotrexate-induced pulmonary lymphoma.

Authors:  Celso T Ebeo; Mirle R Girish; Ryland P Byrd; Thomas M Roy; Jay B Mehta
Journal:  Chest       Date:  2003-06       Impact factor: 9.410

9.  Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas.

Authors:  Wen-hai Feng; Jeffrey I Cohen; Steven Fischer; Li Li; Michael Sneller; Raphael Goldbach-Mansky; Nancy Raab-Traub; Henri-Jacques Delecluse; Shannon C Kenney
Journal:  J Natl Cancer Inst       Date:  2004-11-17       Impact factor: 13.506

  9 in total
  2 in total

1.  Modelling lymphoma therapy and outcome.

Authors:  Katja Roesch; Dirk Hasenclever; Markus Scholz
Journal:  Bull Math Biol       Date:  2013-12-14       Impact factor: 1.758

2.  Diagnosis and management of a patient with primary pulmonary diffuse large B-cell lymphoma: A case report and review of the literature.

Authors:  Ai-Gui Jiang; Xiao-Yan Gao; Hui-Yu Lu
Journal:  Exp Ther Med       Date:  2014-06-20       Impact factor: 2.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.